Aducanumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | beta amyloid |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| Synonyms | BIIB037 |
| CAS Number | 1384260-65-4 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6472H10028N1740O2014S46 |
| Molar mass | 145.9 kg/mol |
Aducanumab is a human monoclonal antibody that is being studied for the treatment of Alzheimer's disease (AD).[1] It is being developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer.[2] The antibody targets aggregated forms of β-amyloid.[3]
Research
Interim results from the second Phase 1 study of the drug were reported at the 12th International Conference on Alzheimer’s and Parkinsons’s Diseases and Related Neurological Disorders (AD/PD 2015), in Nice, France, in March 2015.[1][4] A phase Ib study was published in August 2016 and the phase 3 clinical trial is ongoing.[5]
References
- 1 2 Cynthia Fox for Drug Discovery and Development. April 28, 2015 The Story of Biogen's Alzheimer's Drug, Aducanumab
- ↑ Rebecca Zacks for Xconomy. November 20th, 2007 Biogen Inks $380 Million Deal With Swiss Company
- ↑ Toyn, Jeremy (2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Rev. Clin. Pharmacol. 8 (3): 267–269. doi:10.1586/17512433.2015.1034690. PMID 25860157.
- ↑ Matthew Herper for Forbes. March 20, 2015 Biogen Drug Could Inspire New Hope For Alzheimer's Treatments
- ↑ Sevigny J.; Chiao P.; Bussière T.; Weinreb P.H.; Williams L.; Maier M.; Dunstan R.; Salloway S.; Chen T.; Ling Y.; O'Gorman J.; Qian F.; Arastu M.; Li M.; Chollate S.; Brennan M.S.; Quintero-Monzon O.; Scannevin R.H.; Arnold H.M.; Engber T.; Rhodes K.; Ferrero J.; Hang Y.; Mikulskis A.; Grimm J.; Hock C.; Nitsch R.M.; Sandrock A. (2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature. 537 (7618): 50–56. doi:10.1038/nature19323.
This article is issued from Wikipedia - version of the 11/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.